

## Biomarkers in diagnosis and progression of castration-resistant prostate cancer

Poster Session 36

Sunday, 26 March  
12:15 - 13:45

**Location:** Room Stockholm, North Hall (Level 1)

**Chairs:** I.T.R. Cavarretta, Milan (IT)  
C. Jeronimo, Porto (PT)  
H.G. Lilja, New York (US)

### Aims and objectives of this session

Use of validated prostate cancer biomarkers is important for selection of patients who risk developing aggressive disease and also for monitoring castration therapy resistance. Novel approaches to analyze markers in multifocal prostate cancer will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

\*481

### Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death

**By:** [Na R.](#)<sup>1</sup>, [Zheng S.L.](#)<sup>2</sup>, [Han M.](#)<sup>3</sup>, [Yu H.](#)<sup>2</sup>, [Jiang D.](#)<sup>2</sup>, [Shah S.](#)<sup>2</sup>, [Ewing C.](#)<sup>3</sup>, [Zhang L.](#)<sup>3</sup>, [Novakovic K.](#)<sup>4</sup>, [Petkewicz J.](#)<sup>2</sup>, [Gulukota K.](#)<sup>5</sup>, [Helseth D.](#)<sup>5</sup>, [Quinn M.](#)<sup>2</sup>, [Humphries E.](#)<sup>3</sup>, [Wiley K.](#)<sup>3</sup>, [Isaacs S.](#)<sup>3</sup>, [Wu Y.](#)<sup>1</sup>, [Liu X.](#)<sup>2</sup>, [Zhang N.](#)<sup>1</sup>, [Wang C-H.](#)<sup>2</sup>, [Khandekar J.](#)<sup>5</sup>, [Hulick P.](#)<sup>6</sup>, [Shevrin D.](#)<sup>6</sup>, [Cooney K.](#)<sup>7</sup>, [Shen Z.](#)<sup>1</sup>, [Partin A.](#)<sup>3</sup>, [Carter H.B.](#)<sup>3</sup>, [Carducci M.](#)<sup>8</sup>, [Eisenberger M.](#)<sup>8</sup>, [Denmeade S.](#)<sup>8</sup>, [McGuire M.](#)<sup>4</sup>, [Walsh P.](#)<sup>3</sup>, [Helfand B.](#)<sup>4</sup>, [Brendler C.](#)<sup>4</sup>, [Ding Q.](#)<sup>1</sup>, [Xu J.](#)<sup>2</sup>, [Isaacs W.](#)<sup>3</sup>

**Institutes:**<sup>1</sup>Huashan Hospital, Fudan University, Dept. of Urology, Shanghai, China, <sup>2</sup>NorthShore University HealthSystem, Program for Personalized Cancer Care, Evanston, United States of America, <sup>3</sup>Johns Hopkins University School of Medicine, Dept. of Urology and The James Buchanan Brady Urologic Institute, Baltimore, United States of America, <sup>4</sup>NorthShore University HealthSystem, Dept. of Surgery, Evanston, United States of America, <sup>5</sup>NorthShore University HealthSystem, Center for Molecular Medicine, Evanston, United States of America, <sup>6</sup>NorthShore University HealthSystem, Dept. of Medicine, Evanston, United States of America, <sup>7</sup>University of Utah, Dept. of Internal Medicine, Salt Lake City, United States of America, <sup>8</sup>Johns Hopkins Medical Institutions, Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America

\*482

### Comprehensive molecular dissection of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue based prognostic biomarkers

**By:** [Salami S.](#)<sup>1</sup>, [Hovelson D.](#)<sup>2</sup>, [Mathieu R.](#)<sup>3</sup>, [Kaplan J.](#)<sup>2</sup>, [Susani M.](#)<sup>4</sup>, [Rioux-Leclercq N.](#)<sup>5</sup>, [Shariat S.](#)<sup>3</sup>, [Tomlins S.](#)<sup>2</sup>, [Palapattu G.](#)<sup>1</sup>

**Institutes:**<sup>1</sup>University of Michigan, Dept. of Urology, Ann Arbor, United States of America, <sup>2</sup>University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, <sup>3</sup>Medical University Vienna, Dept. of Urology, Vienna, Austria, <sup>4</sup>Medical University Vienna, Dept. of Pathology, Vienna, Austria, <sup>5</sup>Rennes University Hospital, Dept. of Pathology, Rennes, France

483

### A genomic analysis of metastases-prone localized prostate cancer in a European high-risk population

**By:** [Van Den Broeck T.](#)<sup>1</sup>, [Gevaert T.](#)<sup>1</sup>, [Prekovic S.](#)<sup>2</sup>, [Ong K.](#)<sup>3</sup>, [Tosco L.](#)<sup>1</sup>, [Moris L.](#)<sup>2</sup>, [Smeets E.](#)<sup>2</sup>, [Lehrer J.](#)<sup>3</sup>, [Haddad Z.](#)<sup>3</sup>, [Helsen C.](#)<sup>2</sup>, [Margrave J.](#)<sup>3</sup>, [Van Poppel H.](#)<sup>1</sup>, [Everaerts W.](#)<sup>1</sup>, [Erho N.](#)<sup>3</sup>, [Buerki C.](#)<sup>3</sup>, [Davicioni E.](#)<sup>3</sup>, [Joniau S.](#)<sup>1</sup>, [Claessens F.](#)<sup>2</sup>

**Institutes:**<sup>1</sup>UZ Leuven, Dept. of Urology, Leuven, Belgium, <sup>2</sup>KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, <sup>3</sup>GenomeDx, GenomeDx Biosciences, Vancouver, Canada

484

### Analysing circulating tumour cells with epithelial and mesenchymal features for prostate cancer prognosis

**By:** Xu L.<sup>1</sup>, Mao X.<sup>2</sup>, Guo T.<sup>2</sup>, Chan P.Y.<sup>3</sup>, Shaw G.<sup>4</sup>, Hines J.<sup>4</sup>, Wang Y.<sup>2</sup>, Oliver T.<sup>2</sup>, Ahmad A.<sup>5</sup>, Berney D.<sup>2</sup>, Shamash J.<sup>3</sup>, Lu Y-J.<sup>2</sup>

**Institutes:**<sup>1</sup>Barts Cancer Institute, Center for Molecular Oncology, London, United Kingdom, <sup>2</sup>UnZhongshan Hospital Fudan University, Dept. of Urology, Shanghai, China, <sup>3</sup>Barts Cancer Institute, Centre for Molecular Oncology, London, United Kingdom, <sup>4</sup>Barts Health NHS, Dept. of Medical Oncology, London, United Kingdom, <sup>5</sup>Barts Health NHS, Dept. of Urology, London, United Kingdom, <sup>6</sup>Wolfson Institute of Preventive Medicine, Centre for Cancer Prevention, London, United Kingdom

485

**Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study**

**By:** Gore J.<sup>1</sup>, Du Plessis M.<sup>2</sup>, Santiago-Jimenez M.<sup>3</sup>, Yousefi K.<sup>3</sup>, Thompson D.<sup>4</sup>, Karsh L.<sup>5</sup>, Lane B.<sup>6</sup>, Franks M.<sup>7</sup>, Chen D.<sup>8</sup>, Bandyk M.<sup>9</sup>, Bianco Jr. F.<sup>10</sup>, Brown G.<sup>11</sup>, Clark W.<sup>12</sup>, Kibel A.<sup>13</sup>, Kim H.<sup>14</sup>, Lowrance W.<sup>15</sup>, Manoharan M.<sup>16</sup>, Maroni P.<sup>17</sup>, Perrapato S.<sup>18</sup>, Sieber P.<sup>19</sup>, Trabulsi E.<sup>20</sup>, Waterhouse R.<sup>21</sup>, Davicioni E.<sup>22</sup>, Lotan Y.<sup>23</sup>, Lin DW<sup>1</sup>

**Institutes:**<sup>1</sup>University of Washington, Seattle Cancer Care Alliance, Seattle, United States of America, <sup>2</sup>GenomeDx Biosciences, Clinical Development, Vancouver, Canada, <sup>3</sup>GenomeDx Biosciences, Dept. of Biostatistics, Vancouver, Canada, <sup>4</sup>Emmes Canada, Dept. of Biostatistics, Burnaby, Canada, <sup>5</sup>The Urology Center of Colorado, Dept. of Urology, Colorado, United States of America, <sup>6</sup>Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America, <sup>7</sup>Virginia Urology, Dept. of Urology, Richmond, United States of America, <sup>8</sup>Fox Chase Cancer Center, Surgical Oncology, Philadelphia, United States of America, <sup>9</sup>Lakeland Regional Cancer Center, Dept. of Urology, Lakeland, United States of America, <sup>10</sup>Nova Southeastern University, Urological Research Network, Miami, United States of America, <sup>11</sup>Delaware Valley Urology, LLC, Dept. of Urology, Voorhees, United States of America, <sup>12</sup>Alaska Clinical Research Center, Dept. of Urology, Anchorage, United States of America, <sup>13</sup>Brigham and Womens Hospital, Dept. of Urology, Boston, United States of America, <sup>14</sup>Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, <sup>15</sup>University of Utah, Huntsman Cancer Institute, Salt Lake City, United States of America, <sup>16</sup>University of Miami, Miller School of Medicine, Miami, United States of America, <sup>17</sup>University of Colorado, Anschutz Medical Campus, Aurora, United States of America, <sup>18</sup>University of Vermont Medical Center, Dept. of Urology, Burlington, United States of America, <sup>19</sup>Lancaster Urology, Dept. of Urology, Lancaster, United States of America, <sup>20</sup>Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, United States of America, <sup>21</sup>Carolina Urology Partners, Dept. of Urology, Gastonia, United States of America, <sup>22</sup>GenomeDx Biosciences, Bioinformatics, San Diego, United States of America, <sup>23</sup>UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

486

**The occurrence and therapeutic consequences of androgen receptor copy number gain in prostate cancer patients using Droplet Digital PCR**

**By:** Buelens S.<sup>1</sup>, Claeys T.<sup>1</sup>, Kumps C.<sup>1</sup>, Dhondt B.<sup>1</sup>, Poelaert F.<sup>1</sup>, Nurten Y.<sup>2</sup>, Vynck M.<sup>3</sup>, Thas O.<sup>3</sup>, Ost P.<sup>4</sup>, Vandesompele J.<sup>2</sup>, Lumen N.<sup>1</sup>

**Institutes:**<sup>1</sup>Ghent University Hospital, Dept. of Urology, Ghent, Belgium, <sup>2</sup>Ghent University, Dept. of Pediatrics and Medical Genetics, Ghent, Belgium, <sup>3</sup>Ghent University, Dept. of Mathematical Modelling, Statistics and Bio-Informatics, Ghent, Belgium, <sup>4</sup>Ghent University Hospital, Dept. of Radiation Oncology, Ghent, Belgium

487

**Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling**

**By:** Morgan T.<sup>1</sup>, Singhal U.<sup>1</sup>, Wang Y.<sup>1</sup>, Henderson J.<sup>1</sup>, Niknafs Y.<sup>2</sup>, Qiao Y.<sup>2</sup>, Taichman R.<sup>3</sup>, Zaslavsky A.<sup>1</sup>, Feng F.<sup>4</sup>, Palapattu G.<sup>1</sup>, Chinnaiyan A.<sup>2</sup>, Tomlins S.<sup>2</sup>

**Institutes:**<sup>1</sup>University of Michigan, Dept. of Urology, Ann Arbor, United States of America, <sup>2</sup>University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, <sup>3</sup>University of Michigan, School of Dentistry, Ann Arbor, United States of America, <sup>4</sup>University of California San Francisco, Dept. of Radiation Oncology, San Francisco, United States of America

488

**Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event selecting for FKBP4 driven castration resistance**

**By:** Gsponer J.<sup>2</sup>, Quintavalle C.<sup>2</sup>, Müller D.<sup>1</sup>, Lorber T.<sup>2</sup>, Juskevicius D.<sup>2</sup>, Lenkiewicz E.<sup>3</sup>, Zellweger T.<sup>4</sup>, Barrett M.<sup>3</sup>, Bubendorf L.<sup>2</sup>, Ruiz C.<sup>2</sup>, Rentsch C.<sup>1</sup>

**Institutes:**<sup>1</sup>University Hospital Basel, Dept. of Urology, Basel, Switzerland, <sup>2</sup>University Hospital Basel, Institute for Pathology, Basel, Switzerland, <sup>3</sup>Mayo Clinic Arizona, Dept. of Research, Scottsdale, United States of America, <sup>4</sup>St. Claraspital, Dept. of Urology, Basel, Switzerland

490

**Cell free DNA methylation markers as predictors of treatment response and prognosis for castration-resistant prostate cancer**

**By:** Hendriks R.<sup>1</sup>, Dijkstra S.<sup>1</sup>, Smit F.<sup>2</sup>, Vandersmissen J.<sup>2</sup>, Van De Voorde H.<sup>2</sup>, Mulders P.<sup>1</sup>, Van Oort I.<sup>1</sup>, Van Criekinge W.<sup>3</sup>, Schalken J.<sup>1</sup>

**Institutes:**<sup>1</sup>Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, <sup>2</sup>MDxHealth, Dept. of Research and Development, Irvine, United States of America, <sup>3</sup>Ghent University, Dept. of Statistics and Bio-Informatics, Ghent, Belgium

491

**Expression of neuropilin 2 as predictor for tumour-related death in patients with prostate cancer**

**By:** Borkowetz A.<sup>1</sup>, Toma M.<sup>2</sup>, Füssel S.<sup>1</sup>, Erdmann K.<sup>1</sup>, Hoenscheid P.<sup>2</sup>, Froehner M.<sup>1</sup>, Muders M.<sup>2</sup>, Wirth M.<sup>1</sup>

**Institutes:**<sup>1</sup>TU Dresden, Dept. of Urology, Dresden, Germany, <sup>2</sup>TU Dresden, Dept. of Pathology, Dresden, Germany

492

**Calcium signaling remodeling as a predictive factor of systemic recurrence after radical prostatectomy**

**By:** Perrouin Verbe M.A.<sup>1</sup>, Talagas M.<sup>2</sup>, Garlantezec R.<sup>3</sup>, Schoentgen N.<sup>4</sup>, Uguen A.<sup>2</sup>, Doucet L.<sup>2</sup>, Rosec S.<sup>5</sup>, Nicot M.C.<sup>2</sup>, Gobin E.<sup>2</sup>, Marcorelles P.<sup>2</sup>, Fournier G.<sup>4</sup>, Valeri A.<sup>4</sup>, Mignen O.<sup>6</sup>

**Institutes:**<sup>1</sup>Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, <sup>2</sup>Brest University Hospital, Dept. of Pathology, Brest, France, <sup>3</sup>University Rennes 1, INSERM U1085-IRSET, Rennes, France, <sup>4</sup>Brest University Hospital, Dept. of Urology, Brest, France, <sup>5</sup>Brest University Hospital, INSERM U 1412, Centre D'Investigation Clinique, Brest, France, <sup>6</sup>University of Brest, INSERM U 1078, Brest, France

13:30 - 13:37

**Circulating tumor cells in prostate cancer**

H.G. Lilja, New York (US)